KLRK1 and cancer: Cancers have evolved several means to evade the subsequent immune response to NKG2DL expression12 by dysregulating the NKG2D response further downstream, such as ligand shedding43 44 or immune subversion.16 45 Despite these downstream immune evasion tactics, the root of the cause for NKG2DL expression remains: the cancer phenotype itself.